[8-K] LeMaitre Vascular, Inc. Reports Material Event

Rhea-AI Filing Summary

Arhaus, Inc. (ARHS) – Form 4 insider transaction

• Chief Accounting Officer Christian Sedor exercised 1,000 Restricted Stock Units (code M) on 08/02/2025, converting them to Class A common shares at a cost basis of $0.
• The issuer simultaneously withheld 295 shares (code F) at $8.68 to cover withholding taxes.
• Net result: Sedor’s direct holdings rose by ≈705 shares, bringing his total direct ownership to 3,508 shares.
• All 1,000 RSUs from this grant have now been settled; none remain outstanding.

No open-market purchase or discretionary sale occurred; transactions were part of the company’s equity-compensation program.

Positive

• Net insider ownership increased by 705 shares, signalling continued alignment between the CAO and shareholders, albeit on a small scale.

Negative

• None.

Insights

Equity Analyst

TL;DR: Routine RSU vesting; modest net share increase, neutral signal.

The event reflects standard compensation mechanics rather than an intentional market purchase. Although the CAO’s direct stake grew by roughly 25 % (3,508 vs. 2,803 pre-exercise), the absolute addition of 705 shares (~US$6k at $8.68) is immaterial to both insider ownership structure and market float. Withholding sales were automatic for tax liabilities, not discretionary divestitures. Overall impact on valuation, liquidity or governance is negligible.

false 0001158895 0001158895 2025-08-05 2025-08-05

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 8-K

Current Report

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 5, 2025

LeMaitre Vascular, Inc.

(Exact name of registrant as specified in its charter)

Commission File Number:  001-33092

Delaware		04-2825458
(State or other jurisdiction of		(IRS Employer
incorporation)		Identification No.)

63 Second Avenue

Burlington, MA 01803

(Address of principal executive offices, including zip code)

781-221-2266

(Registrant’s telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Exchange Act:

Title of each class	Trading symbol	Name of exchange on which registered
Common stock, $0.01 par value per share	LMAT	The Nasdaq Global Market

Indicate by checkmark whether the company is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.   ☐

Item 2.02. Results of Operations and Financial Condition.

On August 5, 2025, LeMaitre Vascular, Inc. (the “Company”) issued a press release regarding its preliminary financial and operational results for the quarter ended June 30, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Report.

The information in this Item 2.02, including Exhibit 99.1 attached hereto, is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing.

Disclaimer on Forward-Looking Statements

This current report on Form 8-K contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Statements regarding the Company’s business that are not historical facts may be “forward-looking statements” that involve risks and uncertainties. Forward-looking statements are based on management’s current, preliminary expectations and are subject to risks and uncertainties that could cause actual results to differ from the results predicted. These risks and uncertainties include risks and uncertainties included under the heading “Risk Factors” in the Company’s most recent Annual Report on Form 10-K, as updated by its subsequent filings with the SEC, all of which are available on the Company’s investor relations website at http://www.lemaitre.com and on the SEC’s website at http://www.sec.gov. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. The Company undertakes no obligation to update publicly any forward-looking statements to reflect new information, events, or circumstances after the date they were made, or to reflect the occurrence of unanticipated events.

Item 9.01. Financial Statements and Exhibits.

The following exhibits are furnished or filed as part of this Report, as applicable:

(d) Exhibits.

Exhibit No.		Description
99.1		Press release issued by LeMaitre Vascular, Inc. on August 5, 2025.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

Signature(s)

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

								LeMaitre Vascular, Inc.
Date: August 5, 2025						By:		Dorian LeBlanc /s/ DORIAN LEBLANC
								Dorian LeBlanc Chief Financial Officer

Exhibit Index

Exhibit No.		Description
99.1		Press release issued by LeMaitre Vascular, Inc. on August 5, 2025.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

FAQ

How many Arhaus (ARHS) shares did the CAO acquire on 08/02/2025?

Christian Sedor acquired 1,000 shares through RSU conversion.

Were any shares sold on the open market?

No. The 295 shares marked as disposition were withheld for taxes, not sold on the market.

What is the CAO's new ownership position after the transaction?

Direct beneficial ownership stands at 3,508 Class A shares.

Does this Form 4 indicate bullish insider sentiment?

The filing is administrative; it reflects routine vesting rather than a discretionary buy, so sentiment impact is neutral.

Are any RSUs from this grant still outstanding?

No. All 1,000 RSUs under this award were settled and now show 0 remaining.